Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 3 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Monopar Therapeutics as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- 0 vs. Q3 2023
- Shares held
- 271.4K
- −30.0K (−10.0%) vs. Q3 2023
- Total value
- $91.7K
- −$90.5K (−49.7%) vs. Q3 2023
- New holders
- 4
- 4 more added
- Sold out
- 4
- 2 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MNPR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 95 | $576.1M |
| Q1 2026 | 82 | $341.5M |
| Q4 2025 | 74 | $360.8M |
| Q3 2025 | 56 | $354.3M |
| Q2 2025 | 43 | $113.3M |
| Q1 2025 | 35 | $109.4M |
| Q4 2024 | 18 | $57.1M |
| Q3 2024 | 6 | $105.9K |
| Q2 2024 | 12 | $310.1K |
| Q1 2024 | 16 | $268.1K |
| Q4 2023 | 14 | $91.7K |
| Q3 2023 | 14 | $182.2K |
| Q2 2023 | 8 | $164.5K |
| Q1 2023 | 11 | $322.9K |
| Q4 2022 | 10 | $471.0K |
| Q3 2022 | 10 | $314.0K |
| Q2 2022 | 13 | $470.6K |
| Q1 2022 | 13 | $519.8K |
| Q4 2021 | 13 | $657.2K |
| Q3 2021 | 9 | $964.4K |
| Q2 2021 | 10 | $1.10M |
| Q1 2021 | 13 | $1.21M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Monopar Therapeutics; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 48,086 | $16.0K | 0.00% | +48,086 | New |
| Vanguard Group Inc | 45,167 | $15.4K | 0.00% | −42,429−48.4% | Reduced |
| Geode Capital Management, LLC | 41,199 | $14.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 29,341 | $9.98K | 0.00% | +10,333+54.4% | Added |
| Gerber, LLC | 28,005 | $9.53K | 0.01% | +28,005 | New |
| Virtu Financial LLC | 27,170 | $9.00K | 0.00% | +27,170 | New |
| Two Sigma Investments, LP | 14,302 | $4.87K | 0.00% | +14,302 | New |
| UBS Group AG | 11,899 | $4.05K | 0.00% | +11,827+16,426.4% | Added |
| Susquehanna International Group, LLP | 10,993 | $3.74K | 0.00% | +532+5.1% | Added |
| Rappaport Reiches Capital Management, LLC | 10,695 | $3.64K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,618 | $1.23K | 0.00% | −109−2.9% | Reduced |
| Morgan Stanley | 800 | $272 | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 80 | $27 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 37 | $13 | 0.00% | +4+12.1% | Added |
| Windsor Advisory Group, LLC | 0 | $0 | 0.00% | −89,974−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −24,663−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −13,078−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −4−100.0% | Sold out |